Compare Mondaycom Ltd (MNDY) vs Novartis AG (NVS) Price & Performance

MNDY trades at $83.67, down 8.13% over 24 hours amid a bearish technical signal, though it holds above key support at $82. The company reported strong Q2 2026 earnings, beating EPS estimates with $1.48 actual versus $1.11 expected, and maintains robust revenue growth, with 2025 revenue at $1.23 billion. Analyst sentiment remains positive with a consensus buy rating and a $106 price target, reflecting confidence in its enterprise software growth and AI monetization.

The outlook for MNDY is cautiously optimistic, supported by consistent earnings beats and high gross margins of 88.74%, but risks include heightened competition in SaaS and potential volatility from its elevated P/E ratio of 35.4. The stock's current dip may present a buying opportunity for growth-oriented investors, contingent on sustained execution and market conditions.

Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.

While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.